These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 30411183)

  • 1. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept for the treatment of rheumatoid arthritis.
    Zhao S; Mysler E; Moots RJ
    Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GP2015 as a promising therapy for rheumatoid arthritis.
    Fitton J; Giollo A; Buch MH
    Expert Opin Biol Ther; 2018 Apr; 18(4):477-481. PubMed ID: 29558865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
    Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
    Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis.
    Song YW; Park YB; Kim J
    Expert Opin Biol Ther; 2021 Jan; 21(1):1-8. PubMed ID: 31801395
    [No Abstract]   [Full Text] [Related]  

  • 12. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort.
    Kawakami T; Masui S; Onishi A; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Shimada T; Nakagawa S; Matsuda S; Morinobu A; Terada T; Yonezawa A
    Mod Rheumatol; 2024 Oct; 34(6):1135-1141. PubMed ID: 38516944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
    Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept biosimilars.
    Azevedo VF; Galli N; Kleinfelder A; D'Ippolito J; Urbano PC
    Rheumatol Int; 2015 Feb; 35(2):197-209. PubMed ID: 24980068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of adult patients with JIA treated with the biosimilar Benepali
    Vollbach K; Tenbrock K; Wagner N; Horneff G; Klein A; Foeldvari I; Haas JP; Aries P; Gauler G; Striesow F; Hoff P; Scholz C; Tatsis S; Seipelt E; Klotsche J; Minden K
    Arthritis Res Ther; 2022 Dec; 24(1):271. PubMed ID: 36514116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.